Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Helena Mora-Jensen, BS, Edgar G. Rizzatti, MD,PhD, Adrian Wiestner, MD,PhD

Blood (2006) 108 (11): 4397.

https://doi.org/10.1182/blood.V108.11.4397.4397

Published: 2006

Journal Articles

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Elinor Lee, BS, Yuji Miura, MD/PhD, Raymond Lai, MD/PhD, Masanori Daibata, MD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 4393.

https://doi.org/10.1182/blood.V108.11.4393.4393

Published: 2006

Journal Articles

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Raymond Lai, MD/PhD, Masanori Daibata, MD, Therese White, RN, Kieron Dunleavy, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 830.

https://doi.org/10.1182/blood.V108.11.830.830

Published: 2006

Journal Articles

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Edgar G. Rizzatti, MD, PhD, Helena I. Mora-Jensen, Eric Billings, PhD, Raymond Lai, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2005) 106 (11): 2412.

https://doi.org/10.1182/blood.V106.11.2412.2412

Published: 2005

Journal Articles

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Adrian Wiestner, MD, PhD, Kieron Dunleavy, MD, Edgar G. Rizzatti, MD/PhD, Hui Liu, Msc, Gerald E. Marti, MD, Therese White, RN, Wyndham Wilson, MD/PhD

Blood (2005) 106 (11): 4744.

https://doi.org/10.1182/blood.V106.11.4744.4744

Published: 2005

NARROW

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only